Patents by Inventor Kenneth S. Graham

Kenneth S. Graham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250121030
    Abstract: The present invention provides ophthalmic formulations having high concentrations of vascular endothelial growth factor (VEGF) receptor fusion protein and high stability during storage. Methods for treating angiogenic eye disorders using the high concentration formulations are also provided.
    Type: Application
    Filed: December 17, 2024
    Publication date: April 17, 2025
    Inventors: Kenneth S. GRAHAM, Saurabh WADHWA
  • Publication number: 20250041411
    Abstract: The present invention provides stable liquid pharmaceutical formulations comprising a human bispecific antibody that specifically binds to human BCMA and human CD3. In certain embodiments, the formulations contain, in addition to the bispecific antibody, a buffer, a surfactant, and a sugar. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability upon stress and storage.
    Type: Application
    Filed: July 5, 2024
    Publication date: February 6, 2025
    Inventors: Kenneth S. Graham, Saurabh Wadhwa, Douglas Kamen
  • Patent number: 12168036
    Abstract: The present invention provides ophthalmic formulations having high concentrations of vascular endothelial growth factor (VEGF) receptor fusion protein and high stability during storage. Methods for treating angiogenic eye disorders using the high concentration formulations are also provided.
    Type: Grant
    Filed: July 23, 2021
    Date of Patent: December 17, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kenneth S. Graham, Saurabh Wadhwa
  • Patent number: 12077593
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: September 3, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • Publication number: 20240280551
    Abstract: The inventions provide methods for monitoring column performance and operating chromatography column by applying generalized linear model to system suitability parameters (SSPs) to assess how fast the column is aging and whether the column stationary phase needs to be replaced. The methods will lead to faster identification of column failures and help maintain high separation quality and consistent analytical results for analytical and preparative chromatography methods. Columns evaluated and/or monitored by the methods and products resulting from use of the columns and methods also are provided.
    Type: Application
    Filed: February 22, 2024
    Publication date: August 22, 2024
    Inventors: Shao-Chung Wang, Tse-Hong Chen, Kenneth S. Graham
  • Publication number: 20240245779
    Abstract: The disclosure provides methods of determining an initial amount of surfactant to include in a liquid pharmaceutical composition comprising a protein, intended for administration to a subject as an IV admixture. The methods comprise determining the degradation rate of the surfactant, the minimum amount of surfactant whereby stability of the protein is maintained in IV admixture the end of shelf-life of the liquid pharmaceutical composition, and, based on the degradation rate, shelf-life, and minimum amount of surfactant, determining a target amount of surfactant to include in the composition at the time of formulation.
    Type: Application
    Filed: January 24, 2024
    Publication date: July 25, 2024
    Inventors: Douglas E. KAMEN, Kenneth S. GRAHAM, Caterina RICCARDI
  • Publication number: 20240058418
    Abstract: The present invention provides ophthalmic formulations having high concentrations of vascular endothelial growth factor (VEGF) receptor fusion protein and high stability during storage. Methods for treating angiogenic eye disorders using the high concentration formulations are also provided.
    Type: Application
    Filed: September 12, 2023
    Publication date: February 22, 2024
    Inventors: Kenneth S. Graham, Saurabh Wadhwa
  • Publication number: 20210353714
    Abstract: The present invention provides ophthalmic formulations having high concentrations of vascular endothelial growth factor (VEGF) receptor fusion protein and high stability during storage. Methods for treating angiogenic eye disorders using the high concentration formulations are also provided.
    Type: Application
    Filed: July 23, 2021
    Publication date: November 18, 2021
    Inventors: Kenneth S. Graham, Saurabh WADHWA
  • Patent number: 11103552
    Abstract: The present invention provides ophthalmic formulations having high concentrations of vascular endothelial growth factor (VEGF) receptor fusion protein and high stability during storage. Methods for treating angiogenic eye disorders using the high concentration formulations are also provided.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: August 31, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kenneth S. Graham, Saurabh Wadhwa
  • Patent number: 11098127
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: August 24, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • Publication number: 20210230283
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: April 8, 2021
    Publication date: July 29, 2021
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • Patent number: 11071780
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: July 27, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Robert L. Vitti, Kristine A. Erickson, Karen W. Chu, Stanley J. Wiegand, Jingtai Cao, Ivan B. Lobov, Saurabh Wadhwa, Kenneth S. Graham, Daniel Dix
  • Publication number: 20190343918
    Abstract: The present invention provides ophthalmic formulations having high concentrations of vascular endothelial growth factor (VEGF) receptor fusion protein and high stability during storage. Methods for treating angiogenic eye disorders using the high concentration formulations are also provided.
    Type: Application
    Filed: May 10, 2019
    Publication date: November 14, 2019
    Inventors: Kenneth S. Graham, Saurabh Wadhawa
  • Publication number: 20190117767
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).
    Type: Application
    Filed: December 28, 2018
    Publication date: April 25, 2019
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Robert L. VITTI, Kristine A. ERICKSON, Karen W. CHU, Stanley J. WIEGAND, Jingtai CAO, Ivan B. LOBOV, Saurabh WADHWA, Kenneth S. GRAHAM, Daniel DIX
  • Publication number: 20190002574
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: August 9, 2018
    Publication date: January 3, 2019
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • Patent number: 10072086
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: September 11, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • Publication number: 20170080086
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Robert L. VITTI, Kristine A. ERICKSON, Karen W. CHU, Stanley J. WIEGAND, Jingtai CAO, Ivan B. LOBOV, Saurabh WADHWA, Kenneth S. GRAHAM, Daniel DIX
  • Publication number: 20160144025
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).
    Type: Application
    Filed: November 17, 2015
    Publication date: May 26, 2016
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Robert L. VITTI, Kristine A. ERICKSON, Karen W. CHU, Stanley J. WIEGAND, Jingtai CAO, Ivan B. LOBOV, Saurabh WADHWA, Kenneth S. GRAHAM, Daniel DIX
  • Publication number: 20160002341
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: September 22, 2015
    Publication date: January 7, 2016
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • Patent number: 9173880
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: November 3, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh